✦ LIBER ✦

Three years of treatment with once-yearly zoledronic acid influences the kinetics of bone matrix maturation in osteoporotic patients independent of bone turnover

✍ Scribed by S. Gamsjaeger; B. Buchinger; J. Gasser; E.F. Eriksen; K. Klaushofer; E.P. Paschalis

Book ID: 116324240
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 65 KB
Volume: 48
Category: Article
ISSN: 8756-3282
DOI: 10.1016/j.bone.2011.03.098

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bone material properties in actively bon

Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid

✍ Sonja Gamsjaeger; Birgit Buchinger; Elizabeth Zwettler; Robert Recker; Dennis Bl 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 473 KB

Zoledronic acid (ZOL), a third-generation aminobisphosphonate, showed pronounced antifracture efficacy in a phase III clinical trial [Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT)] when administered yearly (5-mg infusions of ZOL), produci

The effect of three years of TNF alpha b

The effect of three years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study

✍ Suzanne Arends, Anneke Spoorenberg, Pieternella M Houtman… 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 215 KB

AOSOP6 Results from the 2-year open-labe

AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab

✍ A.T. Stopeck; A. Lipton; M. Martín; J-J. Body; A. Paterson; G.G. Steger; K. Tonk 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB